共 8 条
[1]
Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: The tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy study[J] . Mark C.Genovese,James D.McKay,Evgeny L.Nasonov,Eduardo F.Mysler,Nilzio A.da Silva,EmmaAlecock,ThasiaWoodworth,Juan J.Gomez‐Reino.Arthritis & Rheumatism . 2008 (10)
[2]
Double‐blind randomized controlled clinical trial of the interleukin‐6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate[J] . Arthritis & Rheumatism . 2006 (9)
[4]
Clinical studies in patients with Castleman’s disease, Crohn’s disease, and rheumatoid arthritis in Japan[J] . Norihiro Nishimoto.Clinical Reviews in Allergy & Immunology . 2005 (3)
[7]
gp130 AND THE INTERLEUKIN-6 FAMILY OF CYTOKINES[J] . Tetsuya Taga,Tadamitsu Kishimoto.Annual Review of Immunology . 1997
[8]
lnterleukin-6 (IL-6) in Synovial Fluid and Serum of Patients with Rheumatic Diseases[J] . A. J. Swaak,A. Van Rooyen,E. Nieuwenhuis,L. A. Aarden.Scandinavian Journal of Rheumatology . 1988 (6)